Nuclear Medicine and Molecular Imaging Department, VKF American Hospital, Istanbul, Turkey.
Chair for Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany.
Clin Nucl Med. 2021 Aug 1;46(8):656-658. doi: 10.1097/RLU.0000000000003705.
We created our first national clinical protocol of 177Lu-CXCR4 therapy for patient who have failed to respond to current therapy options. We also calculated the kidney, liver, and tumor dosimetry. The kidney's mean absorbed dose was calculated to be 0.45 Gy/GBq, the calculated radiation absorbed dose of the liver was 0.63 Gy/GBq, and the radiation absorbed doses of the tumors vary between 9.2 and 82 Gy/GBq. 177Lu-CXCR4 therapy produced a promising clinical response in our patient in acceptable radiation dose limits as a treatment option in heavily pretreated patients with advanced multiple myeloma.
我们制定了首个用于治疗当前治疗方案失败的患者的 177Lu-CXCR4 治疗的全国临床方案，同时还计算了肾脏、肝脏和肿瘤剂量学。肾脏的平均吸收剂量为 0.45 Gy/GBq，计算出的肝脏吸收剂量为 0.63 Gy/GBq，肿瘤的吸收剂量在 9.2 到 82 Gy/GBq 之间不等。177Lu-CXCR4 治疗在可接受的辐射剂量范围内为我们的患者带来了有希望的临床反应，作为晚期多发性骨髓瘤的重度预处理患者的治疗选择之一。
